Skip to main content
. 2024 Jul 12;103(28):e38911. doi: 10.1097/MD.0000000000038911

Figure 2.

Figure 2.

Patient J experienced recurrent liver and uterine metastases during T-DXd treatment. T-Dxd = Trastuzumab Deruxtecan.